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Available online 27 August 2016AbstractPurpose: To evaluate the efficacy of vitrectomy, membranectomy, and internal limiting membrane (ILM) peeling on macular thickness and best
corrected visual acuity (BCVA) in patients with refractory diffuse diabetic macular edema (DME) and non-tractional epiretinal membrane (NT-
ERM).
Methods: This prospective interventional case series included eyes with refractory DME (central subfield macular thickness [CSMT] > 300 mm)
after at least two intravitreal injections of bevacizumab (IVB) and one intravitreal injection of triamcinolone (IVT), and accompanying
NT-ERM. Complete ophthalmic examination, baseline spectral domain optical coherence tomography (SD-OCT), and fluorescein angiography
(FA) were performed prior to 23 gauge pars plana vitrectomy with membranectomy and internal limiting membrane (ILM) peeling.
Postoperative evaluation was done with clinical examination and SD-OCT. Linear mix model analysis was used to study postoperative results.
Results: Twelve eyes from 11 patients (5 males) with a mean age of 60.33 ± 9.01 (range 46e73 years) were included. The mean follow-up time
was 13.5 ± 4.48 months (range 4e20 months). A significant reduction in CSMTwas found (from 559 ± 89 mm to 354 ± 76 mm; P ¼ 0.001), with
a non-significant BCVA change (from 0.84 ± 0.32 logMAR to 0.72 ± 0.2 logMAR; P ¼ 0.967). There was no significant correlation between
CSMT and BCVA (partial correlation ¼ 0.115, P ¼ 0.445) and also between estimated mean CSMT change per month and estimated mean
BCVA change per month (r ¼ 0.337, P ¼ 0.283).
Conclusion: In this series, our results did not show that vitrectomy, membranectomy, and ILM peeling result in significant improvement of
BCVA in eyes with refractory DME and non-tractional ERM in spite of central macular thickness reduction.
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In diabetes mellitus, impairment of inner and outer blood
retinal barriers may lead to macular edema and subsequent
visual loss.1 There is a high prevalence of visually significant
macular edema in patients with diabetes mellitus, and it can be
progressive.2,3 Diabetic macular edema (DME) has been
classified into focal and diffuse types, the latter considered less
responsive to laser treatment.1,4,5
Currently available options in management of DME are
metabolic control, macular photocoagulation (MPC), intra-
vitreal administration of corticosteroids or anti vascular
endothelial growth factor (VEGF) agents, and various com-
binations of these methods.4,6e8 However, some cases of
DME are refractory to these interventions.9 In some patients,
a mechanical component via vitreomacular traction (VMT)
or tractional epiretinal membrane (T-ERM) may contribute to
pathogenesis of DME. In such cases, performing vitrectomy
and surgical relieving of mechanical traction has been sug-
gested as an effective treatment for DME.10
In patients with no demonstrable tractional component, the
role of vitrectomy is more controversial.1,11e14 Some authors
have suggested that internal limiting membrane (ILM) is an
important contributing factor in the development of DME;
therefore, vitrectomy with ILM peeling may have a role in
treatment of cases with refractory DME without apparent
traction by improving oxygenation of the retina and relieving
“subtle” traction on the retinal surface.1,11e13 In these studies,
anatomical outcomes are generally promising, but visual out-
comes are varied.1,11,12,14
There is another group of patients with refractory DME
who have an ERM over macula without clinical or OCT evi-
dence of mechanical traction (non-tractional ERM: NT-ERM).
The results of vitrectomy in patients with refractory DME andFig. 1. Left: Preoperative horizontal OCT scan showing properties of “non-tractiona
without visible tautness or retinal striae in biomicroscopic examination, points of fo
The same eye 9 months following vitrectomy, membranectomy, and internal limitin
can be seen.NT-ERM are not clearly known. The aim of this study was to
investigate the potential role of surgical treatment in these
patients.
Methods
This non-comparative prospective interventional case series
was conducted from September 2012 to March 2015. Tenets of
the Helsinki Declaration were followed. Informed consent was
obtained from all patients.
Fluorescein angiography (FA) was performed for all eyes,
and eyes with proliferative diabetic retinopathy or non-
regressed proliferative diabetic retinopathy were treated with
panretinal photocoagulation prior to entering the study.
The inclusion criteria were presence of refractory diffuse
DME and a NT-ERM. Refractory DME was defined as central
subfield macular thickness (CSMT) > 300 mm as measured by
spectral domain optical coherence tomography (SD-OCT)
(Spectralis, Heidelberg Engineering, Germany) despite gly-
cemic control (hemoglobin A1C of 7.0% or lower) after at
least two monthly intravitreal injection of 1.25 mg bev-
acizumab (IVB) with at least one simultaneous intravitreal
injection of 1 mg triamcinolone acetonide (IVT).
The ERM was defined as a highly reflective membrane at
the vitreomacular interface on SD-OCT. Only eyes with foveal
involvement of ERM were included. NT- ERM was defined as
the presence of an ERM in SD-OCT horizontal raster scans
uniformly attached to macula without visible tautness or
retinal striae on vitreomacular interface in biomicroscopic
examination, points of focal attachment or tentings of the
underlying inner surface of the retina in SD-OCT images
(Fig. 1). If there was any step-off in retinal thickness at the
borders of the membrane-retinal attachment area, the ERM
was considered tractional.l ERM (NT-ERM)”: an ERM in SD-OCT images uniformly attached to macula
cal attachment or tentings of the underlying inner surface of the retina”- Right:
g membrane peeling. Despite reduction in thickness, intraretinal cystoid spaces
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DME or cataract), angiographic macular ischemia, presence of
any systemic condition that was associated with unacceptably
high surgical risks, occurrence of any major perioperative
complication, and loss to follow-up visits in the first three
postoperative months were excluded. Major perioperative
complications were those with significant visual conse-
quences: vitreous loss in combined phaco-vitrectomy pro-
cedures, iatrogenic insult to macula or optic nerve,
endophthalmitis, significant intraoperative/early postoperative
choroidal effusion/hemorrhage, significant intraoperative/
early postoperative vitreous cavity hemorrhage, intraoperative/
early postoperative retinal detachment. In case of later
occurrence of conditions not directly related to DME but with
significant visual consequences, data attributed to periods
following these events were not used. Ophthalmic examina-
tions including refraction, best corrected visual acuity (BCVA)
assessment (Snellen visual acuity and equivalent logarithm of
the minimum angle of resolution (logMAR), applanation
tonometry, and fundoscopy were done for all patients. Base-
line SD-OCT and FA were performed for all patients. Com-
plete ocular examination and SD-OCT were repeated in each
follow-up visit.Method of surgeryAll operations were performed by one surgeon (M.Z.).
Under local or general anesthesia, a 3-port 23-gauge triam-
cinolone acetonide assisted pars plana vitrectomy was done. If
visually significant cataract was present, phacoemulsification
with implantation of intraocular lens in capsular bag was
performed prior to vitrectomy. Following epiretinal membrane
removal and staining with brilliant blue G (MembraneBlue
Dual, D.O.R.C. International), arcade-to-arcade ILM peeling
was performed. In case of peripheral retinal breaks following
laser treatment, air or SF6 tamponade was used. None of the
cases received periocular injection of long acting steroids at
the end of surgery.Table 1













1 M/70 OS Severe NPDR 4 2 1,5,13,15
2 M/71 OS Severe NPDR 4 1 1,5,9,18
3 M/62 OD Regressed PDR 5 2 1,3,7,17
4 F/56 OD Regressed PDR 7 1 1,5,9,13
5 F/46 OD Regressed PDR 4 1 1,4,7,9
6 F/50 OD Regressed PDR 14 2 1,4,6,11,1
7 F/50 OS Severe NPDR 11 2 2,7,10,12
8 F/66 OS Severe NPDR 3 2 3,10,13
9 F/57 OS Regressed PDR 4 2 1,3,9
10 M/73 OS Moderate NPDR 4 2 3,11,13
11 F/66 OS Regressed PDR 5 3 7,9,10,14
12 M/57 OS Severe NPDR 2 1 1,4
NO: number, IVB: intravitreal bevacizumab, IVT: intravitreal triamcinolone, CSM
female, M: male, OD: oculus dexter, OS: oculus sinister, mm: micrometer, logM
retinopathy, NPDR: non-proliferative diabetic retinopathy.Statistical analysisThe analysis of data was performed using SPSS software
version 16.0. All data was reported with mean ± SD. Data did
not have normal distribution. Due to factors which were not
controllable by authors, the time interval between follow-up
visits and length of follow-up periods were not the same for
all patients. Considering these, we used linear mixed model to
analyze changes in BCVA and CSMT throughout the study. As
there was no extreme outlier in quantitative data, we reported
“mean” which for clinicians is more tangible than “median”. P
values < 0.05 were considered statistically significant.
Results
Fourteen eyes from 13 patients were entered in this study.
Two patients were missed to follow-up after first postoperative
month. Data from the remaining twelve eyes (5 males) with a
mean age of 60.33 ± 9.01 (range:46e73) years were used. All
eyes had clear evidence of diabetic retinopathy. Demographic
data are summarized in Table 1. The mean follow-up duration
was 13.5 ± 4.48 (range: 4 to 20) months. Microstructural
pattern of DME was cystoid type in 5 eyes, spongy-cystoid in
4 eyes, and cystoid-subretinal fluid in 3 eyes. Two eyes (No. 8
and No. 11) had juxtafoveal exudates. Severe retinal ischemia
outside the macula was detected on FA in all eyes. Before
entering the study, patients had received a mean of
5.58 ± 3.50 (range: 2e14) IVB and a mean of 1.75 ± 0.62
(range: 1e3) IVT injections. No intravitreal injections were
administered during follow-up period. Two eyes were pseu-
dophakic. Combined phacoemulsification-vitrectomy was
performed for 3 eyes (eye Nos. 9, 11, and 12). The remaining
seven eyes had no significant cataracts initially, but 5 of them
needed cataract surgery throughout the study with a mean
time interval between vitrectomy and cataract extraction of
10.80 ± 2.58 (range: 7e14) months. In three eyes, a subtle
recurrent ERM was detected over the fovea at postoperative











531 318 0.52 0.69
609 196 0.69 1
445 397 0.52 0.69
645 367 0.69 0.52
514 312 1 0.69
4,17,20 623 442 1.52 0.69
,17 714 237 0.69 0.82
454 357 1 1
495 431 1.30 1
595 373 0.69 0.52
637 366 0.52 1
449 307 1 0.69
T: central subfield macular thickness, BCVA: best corrected visual acuity, F:
AR: logarithm of minimum angle of resolution, PDR: proliferative diabetic
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insignificant. In eye No. 5, full thickness macular hole and
retinal detachment developed 11 months after vitrectomy,
which was treated with repeat vitrectomy and silicone oil
instillation. The last available data from this case before
occurrence of retinal detachment (from postoperative month
9) were used for analysis. Mean BCVA (logMAR) changed
from 0.84 ± 0.32 at baseline (range: 0.52e1.52) to
0.72 ± 0.26 at last visit (range: 0.10e1.00). Mean CSMT
changed from 559 ± 89 mm at baseline (range: 445e714) to
354 ± 76 mm (range: 196e511) at last visit. Linear mixed
model analysis showed a significant reduction in CSMT
(P ¼ 0.001), and an insignificant trend of improvement in
BCVA (P ¼ 0.967) were observed (Fig. 2). We found a mean
decrease of 83 mm per 10 months in CSMT (95% CI; range:
36 to 130) (Fig. 1). There was no statistically significantFig. 2. Changes in best corrected visual acuity (BCVA) and central subfield macu
BCVA (P ¼ 0.967; linear mixed model). Top right: line plot shows changes in CS
between change in CSMT and BCVA (partial correlation ¼ 0.115, P ¼ 0.445). Bo
estimated mean BCVA change per month (r ¼ 0.337, P ¼ 0.283).correlation between change in CSMT and BCVA (partial
correlation ¼ 0.115, P ¼ 0.445) (Fig. 2). Linear mixed
model analysis also confirmed this result by showing that each
1000 mm decrease in CSMT would correspond to 0.16
improvement in logMAR BCVA (95% CI: 0.08 to 1.21,
P ¼ 0.758). The estimated mean CSMT change per month did
not statistically significantly correlate with the estimated mean
BCVA change per month (r ¼ 0.337, P ¼ 0.283) (Fig. 2).
At last follow-up visit, compared to baseline, three eyes
gained 3 lines or more, and two eyes lost 3 lines or more of
visual acuity.
Discussion
DME is one of the main causes of visual loss in diabetic
patients and may be refractory to conventional treatment.14 Inlar thickness (CSMT) of the study eyes. Top left: line plot shows changes in
MT (P ¼ 0.001; linear mixed model). Bottom left: scatter plot of correlation
ttom right: Correlation between estimated mean CSMT change per month and
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recommended.10
The role of vitrectomy in cases of refractory DME without
tractional component is more controversial.15e18 Although
some studies have suggested that ILM peeling may help obtain
better results,15,16 others have reported similar results by vit-
rectomy without ILM peeling.17,18 Moreover, ILM removal
has been suggested to have a role in preventing recurrence of
ERM.1
The presence of an ERM does not necessarily mean that
there is mechanical traction on macula. To confirm a tractional
effect of an ERM on macula, visible retinal striae in bio-
microscopic examination, OCT findings of multiple focal at-
tachments or tentings of the underlying inner surface of the
retina, and step-off in retinal thickness at the borders of
membrane-retinal attachment area have all been suggested as
evidences of traction.19 In the absence of these signs, ERMmay
be considered non-tractional. The role of NT-ERMs in patho-
genesis of DME is not clear. One may consider that NT-ERMs
can contribute to DME development via hypothetical mecha-
nisms including exerting subtle tractional forces beyond the
sensitivity of current commercial SD-OCT technology or
interference with nutrition or oxygenation of retina. However,
the potential role of vitrectomy in these cases of refractory
DME is unknown. To the best of the authors' knowledge, our
study is the first to address this subject.
In this study, we performed vitrectomy with mem-
branectomy and ILM peeling for patients with NT-ERM and
refractory diffuse DME. In our experience, we had encoun-
tered some patients refractory to intravitreal anti-VEGF agents
alone, but responsive to addition of intravitreal triamcinolone
acetonide, sometimes with dramatic decreases in CSMT.
Therefore, we decided that it would be necessary to try at least
one intravitreal injection of triamcinolone acetonide before
considering the cases “refractory”.
After vitrectomy, a significant decline in CSMT was
observed. Mean CSMT reduced from baseline
559.25 ± 89.65 mm to final 354.91 ± 76.41 mm. In compari-
son, we found a mean reduction of 83 mm per 10 months in
CSMT. Other studies reported similar results for vitrectomy in
patients with refractory DME and no vitreomacular interface
abnormality.1,20 Kim et al20 performed vitrectomy in combi-
nation with IVT, and macular laser photocoagulation in DME
patients with no ERM and reported a significant decrease in
macular thickness from 433.3 ± 77.9 mm before surgery to
310.1 ± 80.1 mm 6 months after procedure. They also noted a
mild increase in thickness after postoperative month 3. They
divided their patients into 2 groups including cases with DME
refractory to conventional treatment (macular photocoagula-
tion) and cases with DME refractory to anti-VEGF treatment,
and found that the former group showed significantly more
decline in thickness than the latter group. In another study,
Kim et al21 evaluated the efficacy of combined vitrectomy,
IVT, and MPC on macular thickness and BCVA of 40 eyes
with refractory DME with a long-term follow-up of 3 years.
They reported a significant trend toward continuing decline in
macular thickness during the 3 years after operation (reductionfrom 499.1 ± 174.9 mm to 219.4 ± 66.6 mm). Other
studies1,22,23 have found similar results regarding changes in
macular thickness after vitrectomy. All these data support that
vitrectomy is effective in reduction of macular thickness in
cases of intractable DME. Although we found no previous
studies addressing anatomical results of vitrectomy in re-
fractory DME and NT-ERM, anatomical outcomes in our
study are comparable with results of studies on vitrectomy in
refractory DME with no vitreomacular interface abnormality.
Reports on the effect of vitrectomy on BCVA are more
heterogenous. We found no previous study addressing visual
results of vitrectomy in refractory DME with NT-ERM. We
compared our results with studies addressing vitrectomy in
refractory DME without vitreomacular interface abnormality.
Our data showed an insignificant BCVA improvement in the
last follow-up comparable to reported results by Dehghan et al
who reported an insignificant improvement from 1.00 ± 0.80
logMAR to 0.82 ± 0.18 logMAR.1 This is in contradiction
with results from the study of Kim et al20 which reported a
significant improvement in BCVA (from 0.44 ± 0.15 logMAR
to 0.34 ± 0.22 logMAR at 6 months). They found mild
reduction in BCVA after 3 months and attributed it to cataract
progression. Considering these discrepancies, two points are
noteworthy. First, baseline mean BCVA in the study by Kim
et al20 was considerably better than ours and the study by
Dehghan et al. Second, the number of recruited eyes in the
study by Kim et al (28 eyes) was more than our study (12
eyes) and the study by Dehghan et al1 (12 eyes). These dif-
ferences may explain different results, at least partially.
However, significant improvement of BCVA has been re-
ported by other studies21e23 with baseline mean BCVAs
worse than the aforementioned study by Kim et al and by a
study23 with a number of participants comparable to our
study. Moreover, Rosenblatt et al have found worse baseline
visual acuity as the only clinical variable that is associated
with improvement in postoperative visual acuity.22 Therefore,
other factors such as differences in inclusion criteria, previous
treatments, degree of chronicity, macular ischemia, and dia-
betic retinopathy may contribute to literature discrepancy.1
Two eyes (No. 8 and No. 11) in our study had juxtafoveal
exudates which are reported to be an indicator of poorer vi-
sual prognosis.24
When designing this study, partly based on ethical reasons,
the authors decided to perform combined phaco-vitrectomy
surgery only when there was a visually significant cataract at
the entry of the study. Post-vitrectomy cataract development
might be considered as one of the confounding factors in
analysis of our data. Only two eyes of seven phakic eyes that
had not had cataract extraction at first did not need cataract
extraction at the end of study. Considering that one of these
two developed retinal detachment at follow-up month 11 and
was therefore excluded from the study afterward, it seems
reasonable to conclude that the vast majority of phakic eyes
would eventually need cataract surgery following vitrectomy.
This is in accordance with other studies.21,25 The improvement
of visual acuity may partly be secondary to removing the
cataract in some eyes.
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of decreased macular thickness is macular ischemia. Although
we excluded patients with macular ischemia from our study, it
should be noted that in patients with chronic DME, extensive
macular fluorescein leakage can make the diagnosis of mac-
ular ischemia very difficult. On the other hand, all our patients
showed severe ischemia outside the macula. It is hard to rule
out macular ischemia when nearby retina shows severe
capillary non-perfusion. Authors think that undiagnosed
macular ischemia may have an important role in limiting vi-
sual improvement despite anatomic improvement. New im-
aging tools like optical coherence tomography angiography
(OCTA) may help to identify capillary non-perfusion in these
circumstances more accurately.
Preventing of postoperative ERM formation has been sug-
gested as an advantage of ILM peeling.1 Although we
observed subtle evidence of recurrent ERM in 3 eyes at 7, 11,
and 13 months after the first operation, these membranes were
not clinically significant and barely detectable.
There was no statistically significant correlation between
change in CSMT and BCVA. The correlation of estimated
mean CSMT change per month and estimated mean BCVA
change per month was not statistically significant. This
inconsistency between macular thickness and BCVA might
reflect the permanent damage to the retinal tissue, especially
photoreceptors due to ischemia and long-term inflammatory
process. Various inflammatory factors such as cytokines and
VEGF have been introduced as causative factors of DME.26,27
It is well known that ERM can lead to macular edema,
regardless of presence of diabetes. Although development of
an idiopathic ERM in a diabetic patient cannot be completely
ruled out, we believe that ERMs in our patients were sec-
ondary to diabetic ocular disease because all eyes had clear
evidence of diabetic retinopathy. It should be noted that there
is currently no practical way to differentiate a severely
thickened ILM from a NT-ERM in SD-OCT, and our
definition of NT-ERM in this study was based on SD-OCT
findings.
“Taut posterior hyaloids face” is another entity that may be
confused with NT-ERM. In 1992, Lewis et al observed that
vitrectomy can improve visual prognosis in some eyes with
DME and macular traction. They introduced the term “taut
posterior hyaloid” to describe the clinically observed alteration
of the vitreoretinal interface in some patients who benefit from
vitrectomy.28 Since then, there have been similar reports on
the beneficial effects of vitrectomy in these patients.29,30 The
term “taut posterior hyaloid” has been used in literature to
describe the clinical finding of “thickening and traction of
posterior hyaloid membrane”29 or “premacular posterior hya-
loid which was attached and appeared taut”.30 Recently, this
term has been used much less commonly than previous years,
probably due to increasingly sensitive OCT devices, which can
define characteristics of vitreomacular interface much more
precisely, compared to clinical examinations. However, the
main feature of a “taut posterior hyaloid” is visible evidence
of traction or tautness in clinical exam. On the other hand,
a prerequisite of defining a membrane as “NT-ERM” is lackof any visible evidence of traction or tautness in clinical
examination.
The small number of eyes is the major limitation of our
study which was at least partly due to strict inclusion criteria.
Heterogeneous follow-up schedules were another important
limitation. We tried to minimize the detrimental effect of this
limitation by using linear mixed model to analyze our data.
Also, we did not have a control group of patients treated with
alternative modalities.
The definition of refractory DME differs in various studies.
In older studies refractory or persistent DME is defined based
on response to macular laser photocoagulation.23,31 After
introducing anti VEGF agent, new definitions of refractory
DME were used. For example, in the study by Yuksel et al on
the role of intravitreal bevacizumab in refractory DME, cases
with central foveal thickness >300 mm following at least one
previous focal laser photocoagulation with or without an
intravitreal or subtenon injection of triamcinolone acetonide
was considered to have refractory DME.32 This heterogeneity
in defining refractory DME is reflected in recent studies.33e35
Recently, Hussain et al have found that there are no standard
protocols for defining ‘treatment failure’.36 It seems that there
is no consensus on the definition of refractory DME and this
should be considered when comparing outcomes of various
studies.
In conclusion, our study showed that vitrectomy with
membranectomy and ILM peeling cannot statistically signifi-
cantly improve BCVA despite reducing central macular
thickness in eyes with refractory DME and non-tractional
ERM. However, we cannot generalize this conclusion to
eyes in earlier stages and less protracted course. Based on
similarities in anatomical and visual outcomes, we think that
in patients with non-tractional ERM, pathogenesis of re-
fractory DME is more similar to the pathogenesis of refractory
DME in patients without vitreomacular interface abnormal-
ities rather than patients with tractional vitreoretinal interface
abnormalities. Future studies with a long-term follow-up,
larger population size, proper control group, and more ho-
mogenous follow-up schedules may help to further elucidate
the contribution of non-tractional ERM in the pathogenesis of
refractory DME and the role of vitrectomy in its treatment.
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